Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial)
- PMID: 20536293
- DOI: 10.1517/14656566.2010.497142
Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial)
Abstract
The safety and efficacy of exenatide once weekly is evaluated over 52 weeks in the DURATION-1 trial in patients with type 2 diabetes. This long-acting glucagon-like peptide 1 receptor agonist given as a once weekly subcutaneous injection was found to produce better glycemic control as compared to twice daily exenatide and had a good safety profile over the trial period. Its use can help to reduce the complexity of drug regimen in patients with type 2 diabetes while maintaining a good safety and efficacy profile.
Comment on
-
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.Diabetes Care. 2010 Jun;33(6):1255-61. doi: 10.2337/dc09-1914. Epub 2010 Mar 9. Diabetes Care. 2010. PMID: 20215461 Free PMC article. Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources